Transformed cell lines producing human monoclonal antibodies specific for Pseudomonas aeruginosa serotypes

Abstract

The present invention relates to human monoclonal antibodies capable of plurally binding with O-antigens of Pseudomonas aeruginosa, relates to novel parent cell lines for producing human hybridomas derived from human immunoglobulin synthesizing cells, which cell lines themselves incapable of producing human immunoglobulin and capable of fusing with human antibody-producing cells, relates to human-human hybridomas which can secrete monoclonal antibodies capable of binding with at least one of serotypes of Pseudomonas aeruginosa, relates to pharmaceutical compositions for prophylaxis or therapy of Pseudomonas aeruginosa infectious diseases, and relates to prophylactic or therapeutic methods for Pseudomonas aeruginosa infectious diseases.

What is claimed is: 
     
       1. A transformed cell line selected from the group consisting of FERM BP-1599, FERM BP-1598, FERM BP-1596, and FERM BP-1600. 
     
     
       2. A human monoclonal antibody which is specific for Pseudomonas aeruginosa groups A and F, produced by a cell line FERM BP-1599 and having the binding characteristics thereof. 
     
     
       3. A human monoclonal antibody which is specific for Pseudomonas aeruginosa groups D and I, produced by a cell line FERM BP-1598 and having the binding characteristics thereof. 
     
     
       4. A human monoclonal antibody which is specific for Pseudomonas aeruginosa groups E and F, produced by a cell line FERM BP-1596 and having the binding characteristics thereof. 
     
     
       5. A human monoclonal antibody which is specific for Pseudomonas aeruginosa groups G and H, produced by a cell line FERM BP-1600 and having the binding characteristics thereof.